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Even though cancer researchers nowadays are trying to develop many key cellular pathways susceptible to be tackled by thera-
peutic approaches, we are far from being able to consider some 
cancers as curable diseases in general terms. From a pharmaco-
dynamic point of  view, the main potential molecular targets in-
volved are driver oncogenes, tumor suppressor genes, growth fac-
tors and their receptors, transcription factors, tyrosine kinases, and 
cell adhesion molecules. If  we consider possible targets at higher 
organization levels, we can intervene in aspects such as chromatin 
organization, tumor microenvironment, angiogenesis, apoptosis, 
senescence, mitochondria metabolism, and immune pathways.
 On the other hand, the Pan-cancer genome and tran-
scriptome have been analyzed in more than 1500 pediatric leuke-
mias and solid tumors. This analysis evidenced, for example, that 
pediatric central nervous system tumors are genetically different 
from their adult counterparts. In the meantime, whole-genome 
sequencing analysis of  more than 2,500 tumors has already been 
done which is a continuing evolving genomic effort. A recon-
struction of  the life history and evolution of  mutational process-
es and driver mutation sequences of  38 types of  tumors have 
been throughout analyzed in detail. This unveiled different chro-
mosomal and gene abnormalities are present at different stages 
of  the tumorigenesis process.1 
 All the aforementioned means an essential part of  the 
fascinating cancer machinery and the new therapeutics that have 
been designed for many of  the cellular targets are described with 
different levels of  success. Regarding oncogenes, it´s noteworthy 
that the RAS family, one of  the most important and frequently 
mutated in many tumors, has not received a “knock-out” yet, 
turning this family as the “Muhammad Ali” of  this cancer story.2
 Some recently developed novel drugs such as AMG 510, 
that is directed to the G12C niche within K-Ras, are being tested 
nowadays in the clinics with promising results in some tumors 
such as advanced non-small-cell lung cancers.3 Other cellular-re-
lated Ras pathways such as phosphatidylinositol-3-kinase (PI3K/ 
AKT) and mammalian target of  rapamycin (mTOR) have their 
own designed drugs that proved their worth, though to a lesser 
extent, in some tumor clinical settings.4
 Regarding tumor suppressor genes, things tend to be-
come more difficult and challenging for the moment, as a puta-
tive therapeutic agent must restore something that is missing or 
grossly inefficient. P53, one of  the deoxyribonucleic acid (DNA) 
guardians and most well-known tumor suppressor genes, is be-
ing part of  intensive research in relation to drugs that can “do 
something” at this level.5 Nevertheless, more than one hundred 
different P53 mutations yet described tell us about its complexity.
 Growth factor family and their related receptor path-
ways are other branches of  intensive research with clinical suc-
cess. The discovery of  the human epidermal growth factor re-
ceptor (HER) family, a transmembrane epidermal-growth-factor 
(EGF) family of  receptors, has been one of  the outstanding basic 
cancer research achievements of  the past three decades with im-
mediate clinical translation impact: HER-2 has been found to be 
completely blocked by Herceptin (Trastuzumab), a monoclonal 
antibody, combined with chemotherapy, has saved many lives in 
HER-2 positive early and advanced breast cancer.6
 Other “cousins” of  Herceptin are also already in the 
clinical setting, proving their efficacy and medical benefits: Per-
tuzumab, Trastuzumab emtansine, Lapatinib, etc. Another clas-
sic EGF receptor family blocker, Cetuximab, has rendered good 
clinical results when combined with chemotherapy in wild-type 
Kirsten rat sarcoma viral oncogene homolog (K-RAS) advanced 
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and recurrent colorectal and squamous head and neck cancers.7,8
 Tyrosine kinases (TKS) are other neuralgic druggable 
targets. Anticancer agents of  novel molecular design types, the 
so-called “small molecules”, can act as inhibitors of  the uni-ki-
nase or multi-kinase TKS points and their downstream pathways 
(mTOR, AKT). The “first in class” of  this kind of  inhibitors was 
Imatinib, “the drug of  the new millennium” (launched in 2001), 
specifically designed to target the TK domain within the Phila-
delphia chromosome BCR-ABL region in chronic myeloid leuke-
mias. This drug is used to treat, with outstanding results (overall 
survival of  more than 15-years), refractory patients previously 
considered as chemo-reluctant.9
 A very recent review10 emphasizes that there are current-
ly more than fifty small molecules that function as TKS inhibi-
tors used to treat a broad spectrum of  malignancies. Renal clear 
cell carcinoma is a type of  tumor that has obtained an important 
clinical benefit from these kinds of  compounds (Sunitinib, Pazo-
panib, Sorafenib). Considering other druggable targets, transcrip-
tion factors are at present a current area of  new and intensive 
research, with many transcription factor inhibitors in early clinical 
phases of  development.11
 Chromatin organization/reorganization in cancer is 
complex, and its implications in euchromatin/heterochroma-
tin rate, “readable” genes, nucleosome composition and cell epi-
genetics, are other future challenging roads to go through. This 
led to the appearance of  epigenetic therapy. Hypomethylating 
agents are chromatin-targeted drugs with known beneficial ef-
fects in hematologic premalignancy as myelodysplastic syndromes 
and some blood cancers such as acute myeloid leukemia (AML).12
 But cancer also develops many more alterations at 
higher organization levels than the molecular one. At the cellular 
level, this means self-suffiency to growth signals, evasion from 
growth-inhibitory ones, evasion from apoptosis, limitless replica-
tive potential, survival after cell-cell detachment, altered energy 
metabolism, and acquisition of  other special capabilities. Among 
these last ones, cell motility, invasiveness, and survival during the 
travel and settlement in new and not-friendly metastatic niches.13 
Tumor cells may also acquire not only immunologic escape abili-
ties but also the power of  inducing T-cell death. At the tissue 
level, there are marked alterations in fluid dynamics, as normal 
plasma passage to tissues is subjected to more interstitial pressure 
constraints and a new set of  capillaries developed through neo-
angiogenesis.
 For all these pharmacodynamic roads to target, only 
the angiogenesis inhibition and immune-directed therapies have 
proved to be important therapeutic tools today in the clinical are-
na. Angiogenesis is key in tumor feeding and an inflection point 
to tumor malignization. Nutrients and oxygen are delivered to the 
cancer cells from new modified “tube formation”: an abnormal 
and fenestrated capillary network that results in heterogeneous 
and rather chaotic tumor irrigation that difficult the administra-
tion of  therapeutic agents.
 One of  the first “mammoths”, able to disrupt the devel-
opment of  these new capillaries by targeting the vascular endo-
thelial growth factor receptor (VEGFR), was the monoclonal an-
tibody Bevacizumab. With this drug, the treatment of  advanced 
and non-advanced colorectal, cervical and ovarian cancers be-
came a reality. At present, continuous research in this area has de-
veloped fewer toxic antiangiogenics (“less bleeding ones”, mainly 
of  the small-molecules type) that are already in the clinical arena 
(already mentioned “renal cancer drugs” are some examples).10,14
 Cancer immunology today highlights its relevance as a 
“new cancer science”. George Bernard Shaw was right, in “The 
doctor´s dilemma” play from 1906, when one of  the actors states: 
“there is at bottom only one genuine scientific treatment for all diseases and 
that is to stimulate phagocytes”. This was unconsciously referring to 
the innate immunology. The same type of  discovery was made 
by Metchnikoff, “the father of  phagocytosis”, nearly at the same 
time.15
 There are different types of  these kinds of  immune 
therapies, but at present, the most explored and promising ones 
are the checkpoint inhibitors (CPIs).16 Monoclonal antibodies 
such as Ipilimumab, Nivolumab, and Pembrolizumab are com-
pounds of  this class, leading to a new therapeutic concept in can-
cer immunology. These compounds allow natural killer cells “to 
eat tumors”, strictly speaking, inhibiting or eliminating the nega-
tive immune regulation induced by the tumor.17
 CPIs demonstrated a significant increment in advanced 
melanoma survival, with important visceral responses and achiev-
ing, in some cases, complete responses, “the cure”. This made to 
recall the prior days as a Resident in Oncology. At that time, in 
1987, Dr. Steven Rosenberg’s discovery was fascinating such as 
high-dose interleukin-2 treatment delivered in the Intensive Care 
Unit that rendered some patients with peculiar tumor responses, 
mainly in renal cancers and melanoma.18 And when complete, 
they were long-lasting! This was, by that time, the best immuno-
therapy ever known. Unfortunately, it was toxic. The cytokine and 
white blood cell storm induced by these high doses of  interleu-
kin-2 was in some cases the cause of  the patient’s death. Hence, 
this treatment was avoided.
 Nowadays, CPIs such as Pembrolizumab are standard 
of  care in different tumor settings as head and neck cancer, re-
nal cell carcinoma, non-small cell lung cancer, liver cancer, and 
microsatellite instability- (MSI) agnostic tumors. More “complex-
designed” immunotherapies are both in early and advanced devel-
opmental phases, such as novel vaccines and oncolytic therapies 
with adenoviruses. Finally, chimeric antigen receptor (CAR) T-cell 
therapy is a newly designed concept that has changed the natural 
history of  some advanced refractory blood cancers, yet to prove 
its worth with solid tumors.19
 Regarding higher organization levels like tumor tis-
sue structure and pathophysiology, other complex factors of  
tumorigenesis came up to focus, such as cell de-differentiation, 
epithelial-mesenchymal transitions, tumor mutation rate, clonal 
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expansion rates, and complex and dynamic cellular interactions. 
Among these, different competitions and cooperations take place 
between tumor clones, tumor cells from different differentiation 
stages (for example, proliferating tumor cell/tumor stem cell rate) 
and between tumor cells and other cells from the microenviron-
ment.20,21
 Indeed, the whole tumor microenvironment may be 
completely altered, as previously normal cells from the stroma 
(fibroblasts, adipocytes) may have been converted by the tumor 
in tumor-associated cells that begin to work for its maintenance.22 
All these mentioned cellular processes lead to a different level of  
tumor complexity and heterogeneity, becoming this last one, the 
main cause of  treatment resistance, and tumor recurrence. This 
converts all these phenomena into a fascinating and challenging 
druggable target.
 From an integrative point of  view, cancer involves dy-
namic genetic alterations as well as tumor-host interactions that 
determine the destiny of  the tumor and the host.23 Among the 
last ones, and settled at the whole-organism organization level, 
tumorigenesis begins with a great demand for nutrients from the 
tumor that cannot be satisfied by the host. This causes tumor cells 
to reside in a dismal environment that induces glycolytic meta-
bolic shifts; angiogenesis; and force cells to invade, metastasize, 
and undergo necrosis. Tumor necrosis, particularly in metastases, 
leads to non-specific systemic inflammation, which is the major 
cause of  cancer-related mortality.
 In the end, in front of  a cancer patient and considering 
all the aforementioned scenarios with a critical eye, we can sum-
marize them in four ones. First, which are the tumor oncogenic 
drivers and which the more irrelevant mutations. Second, which 
are the main underlying mechanism/s of  tumor progression. 
Third, how is the inner cell dynamics of  the tumor? And fourth, 
how is the tumor-host interaction. All these four scenarios can 
help us, not only for making better use of  old and novel thera-
peutic agents in use but also with the more complex coming ones 
that will specifically target cellular dynamics.
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